Price Alert

MBX Biosciences Inc. Comm... (MBX)

NASDAQ: MBX · Real-Time Price · USD

17.33

-2.77 (-13.78%)

At close: Sep 25, 2025, 3:59 PM

17.33

0.00%

After-hours: Sep 25, 2025, 05:19 PM EDT

-13.78% (1D)

Bid	12.96
Market Cap	582.17M
Revenue (ttm)	222K
Net Income (ttm)	-77.02M
EPS (ttm)	-6.23
PE Ratio (ttm)	-2.78
Forward PE	-6.54
Analyst	Buy
Dividends	n/a

Ask	21.83
Volume	5,177,908
Avg. Volume (20D)	957,990
Open	17.59
Previous Close	20.10
Day's Range	16.95 - 18.30
52-Week Range	4.81 - 27.50
Beta	0.81
Ex-Dividend Date	n/a

About MBX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MBX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MBX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

8 hours ago New

MBX Biosciences shares are trading lower after the... Unlock content with Pro Subscription

3 days ago

+100%

MBX Biosciences shares are trading higher after the company announced once-weekly Canvuparatide achieved the primary endpoint in a Phase 2 trial.

News

3 hours ago · benzinga.com

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.

1 day ago · seekingalpha.com

MBX Biosciences, Inc. - Special Call

MBX Biosciences, Inc. - Special Call Company Participants Jim DeNike Peter Hawryluk - CEO, President & Director Salomon Azoulay - Chief Medical Officer Conference Call Participants Seamus Fernandez - ...

2 days ago · zacks.com

Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet

The mean of analysts' price targets for MBX Biosciences, Inc. (MBX) points to an 88.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

3 days ago · seekingalpha.com

MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market

MBX Biosciences surged after canvuparatide's Phase 2 data showed strong efficacy and safety in hypoparathyroidism, addressing a significant unmet need. MBX's lead candidate outperformed placebo and co...

3 days ago · investors.com

MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise

Shares of MBX Biosciences catapulted Monday after the company posted promising results for its experimental thyroid disease treatment.

1 month ago · seekingalpha.com

Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

Microbix Biosystems Inc. (OTCQX:MBXBF) Q3 2025 Earnings Conference Call August 14, 2025 10:00 AM ET Company Participants Cameron L. Groome - President, CEO & Director James S.

1 month ago · fool.com

Mbx Biosciences (MBX) Q2 Loss Widens 22%